Stem cell and drug discovery scientists around the world are using our solutions to translate their research into therapies
REPROCELL offers a variety of ready-to-ship products to support Mesenchymal Stem Cell (MSC) research, including iPSC-derived cell lines, media, and other culture reagents. Our cell lines are useful for differentiation and exosome production to promote a variety of disease models for research.
Mesenchymal Stem Cells (MSCs) are involved in a variety of cell therapy and drug discovery programs. REPROCELL can help you drive your next clinical MSC project to success and ensure compliancy with regulatory agencies.
Human Tissue Pharmacology
Human fresh tissue testing bridges the gap between animal studies and clinical trials. We specialize in proof of concept studies in patient-derived living tissues, increasing your clinical success rates and adding commercial value to your preclinical drug assets.
Stem Cell Services for Cell Therapy Manufacturing
GMP iPSC and MSC Master Cell Banks and cells for your cell therapy project. Compliant with regulatory standards of the FDA, EMA, and PDMA.
Alvetex® Bioengineered 3D Tissue Services
Complementing our fresh tissue assays by accurately recreating human biology in bioengineered tissues.
StemEdit Clinical Gene Editing Service
Achieve the genotype you need using CRISPR-SNIPER, before moving on to expensive cell bank manufacturing processes.
Oligonucleotide Synthesis Services
Exceptional quality oligos, delivered worldwide. Custom synthesis, purification, and modification – all based on your requirements.
On the REPROCELL blog
Latest
Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed
Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.
12 May 2025
Epigenetic Modifications: Their Role in iPSC Reprogramming and Differentiation
Explore the critical role of epigenetic mechanisms like DNA methylation and histone modifications in iPSC reprogramming and differentiation. Learn how optimizing epigenetic stability enhances reprogramming efficiency, reduces variability, and ensures safer, more reliable iPSC applications for research and therapy.
02 May 2025
REPROCELL Connects with Maryland Governor Moore During His Japan Visit
Maryland Governor Moore strengthens biotech ties with Japan, highlighting REPROCELL's pivotal role in the Maryland-Kanagawa partnership during his trade mission.
22 April 2025
Exosomes from Stem Cells: iPSC vs. MSC-Derived Exosomes for Aesthetic and Regenerative Medicine
Discover how iPSC and MSC-derived exosomes revolutionize skin rejuvenation and anti-aging treatments in aesthetic medicine. Main Point Summary: The blog explores the potential of exosomes derived from induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) for skin rejuvenation and anti-aging treatments in aesthetic medicine, comparing their effectiveness, mechanisms, and applications.
14 April 2025
Can Stem Cells Revolutionize Sustainable Food Production?
Discover how stem cell technology is transforming sustainable food production, offering ethical and scalable alternatives to conventional meat, dairy, and seafood.
31 March 2025
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Find out about immortalized cells for drug testing
Corporate News
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
05 May 2025
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).
25 April 2025
Gameto Announces FDA IND Clearance for Fertilo utilizing REPROCELL’s StemRNA™ Clinical Seed iPSCs
Gameto's FDA IND clearance for Fertilo marks a milestone as the first iPSC-based therapy enters U.S. Phase 3 trials, leveraging REPROCELL’s StemRNA™ Clinical Seed iPSCs.
06 February 2025
%20vial.jpg)
